Endovascular treatment of femoropopliteal arterial diseases remains controversial. We conducted a Bayesian network meta-analysis of randomized controlled trials aiming to investigate the efficacy differences between paclitaxel- or sirolimus-eluting stents, covered stents, drug-coated balloons, bare metal stents, and percutaneous transluminal angioplasty.
Method:
MEDLINE, Embase, Ovid, and other relevant online material were searched up to October 21, 2020. Primary endpoints were primary patency and target lesion revascularization at 6, 12, and more than 24 months.
Results:
Thirty-eight eligible trials included 6026 patients. In terms of primary patency, drug eluting stents were ranked as the most effective treatment based on the surface under the cumulative ranking curve values at 6 (80.6), 12 (78.4), and more than 24 months (96.5) of follow-ups. In terms of target lesion revascularization, drug eluting stents were ranked as the most effective treatment based on the surface under the cumulative ranking curve values at 6 (90.3), 12 (71.3), and more than 24 months (82.1) of follow-ups. Covered stents and bare metal stents had higher ranks in target lesion revascularization than those in primary patency. Sirolimus stents had a higher rank than paclitaxel stents.
Conclusion:
Drug eluting stents showed encouraging results in primary patency rates and freedom from target lesion revascularization at all phases of follow-up for femoropopliteal arterial diseases. Sirolimus stents appear to be more effective in femoropopliteal segment than paclitaxel stent.
WhiteC.Clinical practice. Intermittent claudication. N Engl J Med. 2007;356(12):1241–1250.
2.
NorgrenLHiattWRDormandyJA, et al. Inter-Society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5–S67.
3.
KleinAJChenSJMessengerJC, et al. Quantitative assessment of the conformational change in the femoropopliteal artery with leg movement. Catheter Cardiovasc Interv. 2009;74(5):787–798.
4.
BurketMW. Drug-eluting stents are the default strategy for superficial femoral artery intervention now. Circulation. 2016;133(3):320–329.
5.
GarciaLA. Endovascular therapy for femoropopliteal disease: drug-eluting stents are not the default therapy. Circulation. 2016;133(3):330–336.
6.
SchillingerMSabetiSLoeweC, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354(18):1879–1888.
7.
KrankenbergHSchluterMSteinkampHJ, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation. 2007;116(3):285–292.
8.
SaxonRRDakeMDVolgelzangRL, et al. Randomized, multicenter study comparing expanded polytetrafluoroethylene-covered endoprosthesis placement with percutaneous transluminal angioplasty in the treatment of superficial femoral artery occlusive disease. J Vasc Interv Radiol. 2008;19(6):823–832.
9.
LuGAdesAE. Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc. 2006;101(474):447–459.
10.
DiasSWeltonNJCaldwellDM, et al. Checking consistency in mixed treatment comparison meta-analysis. Statistics in Medicine. 2010;29(7–8):932–944.
11.
Biondi-ZoccaiGAbbateABenedettoU, et al. Network meta-analysis for evidence synthesis: what is it and why is it posed to dominate cardiovascular decision making?Int J Cardiol. 2015;182:309–314.
12.
DiasSSuttonAJAdesAE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33(5):607–617.
13.
DiasSWeltonNJSuttonAJ, et al. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making. 2013;33(5):641–656.
14.
MillsEJThorlundKIoannidisJP. Demystifying trial networks and network meta-analysis. BMJ. 2013;346:f2914.
15.
LambertPCSuttonAJBurtonPR, et al. How vague is vague? a simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med. 2005;24(15):2401–2428.
16.
BrooksSGelmanA. General methods for monitoring convergence of iterative simulations. J Comput Graphi Stat. 1998;7:434–455.
17.
ChaimaniAHigginsJPMavridisD, et al. Graphical tools for network meta-analysis in STATA. PLoS One. 2013;8(10):e76654.
18.
AlbrechtTWaliszewskiMRocaC, et al. Two-year clinical outcomes of the CONSEQUENT trial: can femoropopliteal lesions be treated with sustainable clinical results that are economically sound. Cardiovasc Intervent Radiol. 2018;41(7):1008–1014.
19.
BausbackYWillfort-EhringerASievertH, et al. Six-month results from the initial randomized study of the ranger paclitaxel-coated balloon in the femoropopliteal segment. J Endovasc Ther. 2017;24(4):459–467.
20.
BausbackYWittigTSchmidtA, et al. Drug-eluting stent versus drug-coated balloon revascularization in patients with femoropopliteal arterial disease. J Am Coll Cardiol. 2019;73(6):667–679.
21.
BecqueminJPFavreJPMarzelleJ, et al. Systematic versus selective stent placement after superficial femoral artery balloon angioplasty: a multicenter prospective randomized study. J Vasc Surg. 2003;37(3):487–494.
22.
BrancaccioGLombardiRStefaniniT, et al. Comparison of embolic load in femoropopliteal interventions: percutaneous transluminal angioplasty versus stenting. Vasc Endovascular Surg. 2012;46(3):229–235.
23.
BuszmanPPNowakowskiPMilewskiK, et al. Clinical randomized trial evaluating novel, microcrystalline, and biocompatible polymer paclitaxel-coated balloon for the treatment of femoropopliteal occlusive disease: the BIOPAC trial. JACC Cardiovasc Interv. 2018;11(23):2436–2438.
24.
ChalmersNWalkerPTBelliAM, et al. Randomized trial of the SMART stent versus balloon angioplasty in long superficial femoral artery lesions: the SUPER study. Cardiovasc Intervent Radiol. 2013;36(2):353–361.
25.
DakeMDAnselGMJaffMR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol. 2013;61(24):2417–2427.
26.
DakeMDAnselGMJaffMR, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4(5):495–504.
27.
DickPWallnerHSabetiS, et al. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv. 2009;74(7):1090–1095.
28.
DudaSHBosiersMLammerJ, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13(6):701–710.
29.
DudaSHBosiersMLammerJ, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol. 2005;16(3):331–338.
30.
DudaSHPusichBRichterG, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation. 2002;106(12):1505–1509.
31.
GeraghtyPJMewissenMWJaffMR, et al. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. J Vasc Surg. 2013;58(2):386–395.
32.
GrimmJMüller-HülsbeckSJahnkeT, et al. Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions. J Vasc Interv Radiol. 2001;12(8):935–942.
33.
IidaOSogaYUrasawaK, et al. Drug-coated balloon vs standard percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal arteries: one-year results of the MDT-2113 SFA Japan randomized trial. J Endovasc Ther. 2018;25(1):109–117.
34.
IidaOSogaYUrasawaK, et al. Drug-coated balloon versus uncoated percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal artery: 2-year results of the MDT-2113 SFA Japan randomized trial. Catheter Cardiovasc Interv. 2019;93(4):664–672.
35.
IidaOUrasawaKKomuraY, et al. Self-expanding nitinol stent vs percutaneous transluminal angioplasty in the treatment of femoropopliteal lesions: 3-year data from the SM-01 trial. J Endovasc Ther. 2019;26(2):158–167.
36.
LuJGuJXuW, et al. Efficacy of drug-coated balloon and common balloon for treatment of superficial femoral artery and popliteal artery arteriosclerosis obliterans: prospective randomized controlled trial. J South Med Univ. 2017;37(3):296–300.
37.
BrodmannMWernerMMeyerDR, et al. Sustainable antirestenosis effect with a low-dose drug-coated balloon: the ILLUMENATE European Randomized Clinical Trial 2-year results. JACC Cardiovasc Interv. 2018;11(23):2357–2364.
38.
CejnaMThurnherSIlliaschH, et al. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol. 2001;12(1):23–31.
39.
JiaXZhangJZhuangB, et al. Acotec drug-coated balloon catheter: randomized, multicenter, controlled clinical study in femoropopliteal arteries: evidence from the AcoArt I trial. JACC Cardiovasc Interv. 2016;9(18):1941–1949.
40.
KrishnanPFariesPNiaziK, et al. Stellarex drug-coated balloon for treatment of femoropopliteal disease: twelve-month outcomes from the randomized ILLUMENATE pivotal and pharmacokinetic studies. Circulation. 2017;136(12):1102–1113.
41.
LairdJASchneiderPAJaffMR, et al. Long-term clinical effectiveness of a drug-coated balloon for the treatment of femoropopliteal lesions. Circ Cardiovasc Interv. 2019;12(6):e007702.
42.
LairdJRKatzenBTScheinertD, et al. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012;19(1):1–9.
43.
LairdJRKatzenBTScheinertD, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3(3):267–276.
44.
LairdJRSchneiderPATepeG, et al. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66(21):2329–2338.
45.
LammerJZellerTHauseggerKA, et al. Sustained benefit at 2 years for covered stents versus bare-metal stents in long SFA lesions: the VIASTAR trial. Cardiovasc Intervent Radiol. 2015;38(1):25–32.
46.
LammerJZellerTHauseggerKA, et al. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). J Am Coll Cardiol. 2013;62(15):1320–1327.
47.
MiuraTMiyashitaYSogaY, et al. Drug-eluting versus bare-metal stent implantation with or without cilostazol in the treatment of the superficial femoral artery. Circ Cardiovasc Interv. 2018;11(8):e006564.
48.
RastanAKrankenbergHBaumgartnerI, et al. Stent placement versus balloon angioplasty for the treatment of obstructive lesions of the popliteal artery: a prospective, multicenter, randomized trial. Circulation. 2013;127(25):2535–2541.
49.
RosenfieldKJaffMRWhiteCJ, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373(2):145–153.
50.
SaxonRRCoffmanJMGoodingJM, et al. Long-term results of ePTFE stent-graft versus angioplasty in the femoropopliteal artery: single center experience from a prospective, randomized trial. J Vasc Interv Radiol. 2003;14(3):303–311.
51.
ScheinertDDudaSZellerT, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7(1):10–19.
52.
ScheinertDSchulteKLZellerT, et al. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial. J Endovasc Ther. 2015;22(1):14–21.
53.
SchillingerMSabetiSDickP, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115(21):2745–2749.
54.
SchneiderPALairdJRTepeG, et al. Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT SFA randomized trial. Circ Cardiovasc Interv. 2018;11(1):e005891.
55.
SchroederHWernerMMeyerDR, et al. Low-dose paclitaxel-coated versus uncoated percutaneous transluminal balloon angioplasty for femoropopliteal peripheral artery disease: one-year results of the ILLUMENATE European randomized clinical trial (randomized trial of a novel paclitaxel-coated percutaneous angioplasty balloon). Circulation. 2017;135(23):2227–2236.
56.
SteinerSWillfort-EhringerASievertH, et al. 12-month results from the first-in-human randomized study of the ranger paclitaxel-coated balloon for femoropopliteal treatment. JACC Cardiovasc Interv. 2018;11(10):934–941.
57.
TepeGGögebakanORedlichU, et al. Angiographic and clinical outcomes after treatment of femoro-popliteal lesions with a novel paclitaxel-matrix-coated balloon catheter. Cardiovasc Intervent Radiol. 2017;40(10):1535–1544.
58.
TepeGLairdJSchneiderP, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131(5):495–502.
59.
TepeGSchnorrBAlbrechtT, et al. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv. 2015;8(1PtA):102–108.
60.
TepeGZellerTAlbrechtT, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358(7):689–699.
61.
VroegindeweijDVosLDTielbeekAV, et al. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: a comparative randomized study. Cardiovasc Intervent Radiol. 1997;20(6):420–425.
62.
WerkMAlbrechtTMeyerDR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5(6):831–840.
63.
XuYJiaXZhangJ, et al. Drug-coated balloon angioplasty compared with uncoated balloons in the treatment of 200 Chinese patients with severe femoropopliteal lesions: 24-month results of AcoArt I. JACC Cardiovasc Interv. 2018;11(23):2347–2353.
64.
TeichgraberULehmannTAschenbachR, et al. Drug-coated balloon angioplasty of femoropopliteal lesions maintained superior efficacy over conventional balloon: 2-year results of the randomized EffPac trial. Radiology. 2020;295(2):478–487.
65.
TeichgraberULehmannTAschenbachR, et al. Efficacy and safety of a novel paclitaxel-nano-coated balloon for femoropopliteal angioplasty: one-year results of the EffPac trial. EuroIntervention. 2020;15(18):e1633–e1640.
66.
GouefficYSauguetADesgrangesP, et al. A polymer-free paclitaxel-eluting stent versus a bare-metal stent for de novo femoropopliteal lesions: the BATTLE trial. JACC Cardiovasc Interv. 2020;13(4):447–457.
67.
DiazMLUrtasunFBarberenaJ, et al. Cryoplasty versus conventional angioplasty in femoropopliteal arterial recanalization: 3-year analysis of reintervention-free survival by treatment received. Cardiovasc Intervent Radiol. 2011;34(5):911–917.
68.
GiacoppoDGargiuloGArutaP, et al. Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. BMJ. 2015;351:h5392.
69.
PoncyljuszWFalkowskiASafranowK, et al. Cutting-balloon angioplasty versus balloon angioplasty as treatment for short atherosclerotic lesions in the superficial femoral artery: randomized controlled trial. Cardiovasc Intervent Radiol. 2013;36(6):1500–1507.
70.
SaxonRRChervuAJonesPA, et al. Heparin-bonded, expanded polytetrafluoroethylene-lined stent graft in the treatment of femoropopliteal artery disease: 1-year results of the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) trial. J Vasc Interv Radiol. 2013;24(2):165–173; quiz 174.
71.
SchneiderJRVertaMJAlonzoMJ, et al. Results with Viabahn-assisted subintimal recanalization for TASC C and TASC D superficial femoral artery occlusive disease. Vasc Endovascular Surg. 2011;45(5):391–397.
72.
HeRYeYLiZ, et al. Restenosis prevention with drug eluting or covered stents in femoropopliteal arterial occlusive disease: evidence from a comprehensive network meta-analysis. Eur J Vasc Endovasc Surg. 2019;58(1):61–74.
73.
KatsanosKSpiliopoulosSKarunanithyN, et al. Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery. J Vasc Surg. 2014;59(4):1123–1133.
74.
AntonopoulosCNMylonasSNMoulakakisKG, et al. A network meta-analysis of randomized controlled trials comparing treatment modalities for de novo superficial femoral artery occlusive lesions. J Vasc Surg. 2017;65(1):234–245.
75.
KatsanosKSpiliopoulosSKitrouP, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7(24):e011245.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
